The completion of this milestone allows Ecopia to initiate the second portion of its clinical trial, the extension phase.
During the dose-escalation portion of this trial, ECO-4601 was administered to 14 patients where no dose limiting toxicity was observed. Ecopia’s extension portion is being initiated and should be completed by the end of second quarter 2007.
The purpose of this trial is dose-selection and evaluation of safety and tolerability of ECO-4601, as well as determination of clinical pharmacokinetics. Ecopia’s phase I trial includes brain, breast, prostate, ovarian, lung, colon or pancreatic cancer patients refractory to the current standard of care
“We are very excited with the fact that no dose-limiting toxicity was observed in the first portion of the trial,” said Dr Pierre Falardeau, president and CEO of Ecopia. “This is clearly a key advantage in developing a novel oncology drug such as ECO-4601.”